[go: up one dir, main page]

WO2022167183A1 - Préparation de fermeture de plaie à base biologique - Google Patents

Préparation de fermeture de plaie à base biologique Download PDF

Info

Publication number
WO2022167183A1
WO2022167183A1 PCT/EP2022/050552 EP2022050552W WO2022167183A1 WO 2022167183 A1 WO2022167183 A1 WO 2022167183A1 EP 2022050552 W EP2022050552 W EP 2022050552W WO 2022167183 A1 WO2022167183 A1 WO 2022167183A1
Authority
WO
WIPO (PCT)
Prior art keywords
preparation according
preparation
cellulose
weight
castor oil
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2022/050552
Other languages
German (de)
English (en)
Inventor
Ernesto Rafael OSORIO BLANCO
Sara Schröder
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beiersdorf AG
Original Assignee
Beiersdorf AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beiersdorf AG filed Critical Beiersdorf AG
Priority to EP22701328.1A priority Critical patent/EP4288121A1/fr
Priority to AU2022216364A priority patent/AU2022216364A1/en
Priority to MX2023009152A priority patent/MX2023009152A/es
Priority to CA3208632A priority patent/CA3208632A1/fr
Publication of WO2022167183A1 publication Critical patent/WO2022167183A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0061—Use of materials characterised by their function or physical properties
    • A61L26/0076—Sprayable compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/26—Cyanate or isocyanate esters; Thiocyanate or isothiocyanate esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/717—Celluloses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/0216—Solid or semisolid forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A61K8/046—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A61K8/345—Alcohols containing more than one hydroxy group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/731—Cellulose; Quaternized cellulose derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
    • A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
    • A61L26/0052—Mixtures of macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0061—Use of materials characterised by their function or physical properties
    • A61L26/0066—Medicaments; Biocides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/23—Carbohydrates
    • A61L2300/232—Monosaccharides, disaccharides, polysaccharides, lipopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/404—Biocides, antimicrobial agents, antiseptic agents

Definitions

  • the present invention relates to a wound closure preparation made from natural-based raw materials, in particular a sprayable biologically-based wound closure preparation.
  • the invention relates to a specially composed wound closure preparation based on ethyl cellulose in combination with castor oil and glycerol.
  • Wound closure preparations are mostly liquid agents that are applied to a wound and close it.
  • the contactless application has the advantage that no additional germs get into the wound through the applicator and large wounds, such as abrasions or burns, can be treated more quickly.
  • a flexible film is formed from the liquid wound closure preparation after application and evaporation of the solvent contained in the wound closure preparation.
  • wound closure agents are, for example, Hansaplast, Wundmed, GooFix, URGO spray plaster. They are based on acrylate systems and/or nitrocellulose.
  • wound closure preparations and the wound closure films formed from them cover the wound without the use of other agents and promote healing.
  • wound closure films are usually not particularly resistant to mechanical stress, so that abrasion of the wound closure film can occur, for example, in connection with clothing.
  • wound closure preparations can contain dispersed or crosslinkable polymers or hydrogels that form a stable film on the wound that cannot be rubbed off so easily and offers reliable protection against the ingress of dirt or microorganisms.
  • polymer films can be 'adjusted' in such a way that water vapor or wound secretion can pass through. This has a positive effect on the healing success.
  • Film-forming, sprayable polymer solutions for producing a wound dressing are known from DE 2343923 A1. It is a film-forming polymer solution that can be sprayed in particular from aerosol containers, which is sprayed in thin layers onto a cut, abrasion or surgical wound to be bandaged or otherwise applied after the solvent has evaporated, forming a thin, coherent film that covers the injury site.
  • the known sprayable wound closure agents only have a covering task/effect. If the wound is contaminated with microorganisms or even an inflamed wound, a separate antiseptic treatment is required beforehand.
  • Antimicrobial agents have long been known to those skilled in the art. Basically, all substances above a certain concentration have a cell-damaging effect and thus also against microbes (e.g. bacteria, fungi), i.e. antimicrobial. Antimicrobial agents are characterized by the fact that the cell-damaging effect on microbes is greater than on the cells of higher organisms (humans, mammals, fish, etc.).
  • AMP antimicrobial peptides
  • liquid dressing materials or liquid plasters are usually sold with a propellant in aerosol containers, the so-called wound dressing sprays, from which they can be sprayed onto the wound if necessary by actuating the valve button.
  • the invention circumvents this disadvantage because, surprisingly, the addition of glycerol makes it possible to use a lower concentration of cellulose and thus to achieve even higher and longer-lasting adhesive strengths on the skin than with preparations of the prior art.
  • Castor oil in which the preparation components are dissolved in a biocompatible solvent so that the solution is low enough in viscosity to be sprayed, alleviates the problems listed above.
  • According to the invention is also a wound closure film that is produced from the preparation and remains on the wound after the solvent has evaporated/evaporated.
  • a smaller amount of cellulose / cellulose derivative is sufficient, due to a synergistic effect, due to the homogenizing effect of the glycerol in the formulation according to the invention to explain. Due to the significantly higher homogeneous distribution of the film, the flexibility of the film increases, which can also be felt when worn on the skin.
  • a wound closure film according to the invention adapts better to the skin, the film does not stretch as much as a film of the prior art and due to the high flexibility of the film formed according to the invention there are no tears in the film when worn on the skin/wound.
  • the main task of the preparation according to the invention and the wound closure film formed from it is reliable wound closure and optionally antiseptic properties which 'clean' the wound, ie kill wound germs, ie have a disinfecting effect and thereby promote wound healing.
  • the former property 'safe wound closure' is often considered the most important property of a plaster or similar product, but is not always achievable.
  • perspiration or sweating often lead to undesired premature detachment from the skin.
  • cellulose is preferably used as the natural polymer.
  • Celluloses with a molar mass of 100,000 to 500,000 g/mol are particularly advantageous.
  • Celluloses with a molar mass of 150,000 to 250,000 g/mol are advantageous.
  • the cellulose or the cellulose derivative surprisingly ensures that the wound secretion can be absorbed and the film can thereby be hydrated ('hydration' of the wound closure film). This allows water to 'diffuse' through the wound closure film. The hydrated film can thus keep the wound moist but not wet, which can support wound healing.
  • glycerine is technical glycerine for the pharmaceutical industry and cosmetic applications. It can therefore contain the usual production-related traces of water (maximum 0.5% by weight). Tests have shown that no difference in performance can be achieved with the purest glycerol (analytical quality).
  • castor oil increases the hydrophobic proportion of the formed film, which leads to increased adhesion of the film to the skin surface.
  • castor oil is understood to mean purified castor oil as permitted for cosmetic and/or medical purposes (density: 0.95-0.97 g/cm 3 ; viscosity: approx. 1000 mPas).
  • the preparation also has a lower content of a second vegetable oil, in particular sunflower oil, in addition to the content of castor oil.
  • This additional vegetable oil ensures even greater water resistance of the film formed from the preparation on the skin.
  • the total oil content is advantageously not higher than 20% by weight.
  • the film plaster system is dispersed in classic organic solvents such as ethyl acetate, alcohols and/or alkanes, which are mainly volatile.
  • the preparation according to the invention contains the classic organic solvents such as ethyl acetate, alcohols and/or alkanes, which are highly volatile. These solvents generally do not pose a hazard to the human body as long as they are applied topically. When choosing solvents, there is a balance between the benefit of wound closure and the harm that a solvent may cause. Some solvents - such as ethyl alcohol or isopropyl alcohol - already have an antiseptic effect themselves, which can further increase the benefit of wound closure preparation.
  • the preparation advantageously has a viscosity in the range of up to 1500 mPas.
  • Liquid dressing materials or liquid plasters are marketed filled with a propellant in aerosol containers, the so-called wound dressing sprays, from which they can be sprayed onto the wound as required by actuating the valve button.
  • Spray plaster systems are known, such as are described in patent specifications DE 2343923, DE 2924042 and EP2196225 B1.
  • the film can also be formed by a pump spray, which means that the use of propellants will no longer be necessary.
  • the system according to the invention also offers to be a carrier for antimicrobial agents.
  • Active ingredients that can otherwise only be released into aqueous systems can be used in the cellulose structure, such as biodegradable active ingredients, AMP Systems (antimicrobial peptides), proteins, enzymes and biguanide systems. This is of particular interest as such active ingredients typically require aqueous systems such as hydrogels to function as an antiseptic active ingredient. These antimicrobial agents can then be used for the antiseptic treatment of wounds as well as the preservation of the preparation.
  • classic antiseptic active ingredients in particular octenidine or its tolerable salts, particularly preferably octenidine dihydrochloride, can also be used with outstanding results in the preparation according to the invention.
  • Active ingredients can also be added to the formulation according to the invention in order to covalently bind different antimicrobial components such as biodegradable active ingredients, proteins, enzymes, peptides and/or small molecules to the polymer. These can then be used for, but not limited to, the antiseptic treatment of wounds as well as the antiseptic preservation of formulations.
  • Biodegradable active ingredients are mostly characterized by their positive charges. These can interact with the membrane of microorganisms through different mechanisms and often 'destroy' these microorganisms. The length of the active ingredients and their flexibility play an important role here. AMPs are particularly interesting. These are sometimes more stable than proteins and enzymes to solvent and pH of the medium. In addition, AMPs are characterized by their rapid effect. In research, combinations of positively charged amino acids, such as lysine or arginine, and long, lipophilic amino acids, such as phenylalanine or tryptophan, have proven to be very effective. There is also a large number of different AMPs that consist of either short peptide sequences (2-8 amino acids) or long peptide sequences (10 to 40) and show different effectiveness.
  • Tripeptides which have shown an antimicrobial effect preferably consist of a combination of arginine, tryptophan and/or phenylalanine and preferably have a structure with the following sequence: positively charged amino acid - hydrophobic and sterically demanding amino acid - positively charged amino acid. It is also known that modifications, for example by the attachment of protective groups, even at unusual sites, such as multiple tert-butylations on the aromatic ring of tryptophan, have a positive effect on the antimicrobial properties of such AMPs. According to the invention, it is also conceivable to use longer peptides than AMP for this invention.
  • Palmitoyl Tripeptide-3/5 which, in addition to a low antimicrobial effect, also simulates the naturally occurring thrombospondin-1 (TSP-1 sequence: Pal-Lys-Val-Lys; SYN®-COLL), which in turn Promotes the formation of collagen, which also supports wound healing.
  • TSP-1 sequence Pal-Lys-Val-Lys; SYN®-COLL
  • Longer peptides such as the RRP9W4N from Red dead Discovery AB also showed good antimicrobial properties and can also be used for this invention, as well as AMPs of the LL-37 families, defensin peptides and bacterial permeabilizing proteins (BPI). Longer peptides from the same amino acid can also be used for this invention, such as e-poly-L-lysine.
  • biodegradable active ingredients for example, biodegradable active ingredients, AMP systems (antimicrobial peptides), proteins or enzymes are preferably used as antiseptic active ingredients.
  • AMP systems antiseptic peptides
  • proteins or enzymes are preferably used as antiseptic active ingredients.
  • AMPs are particularly preferred as antimicrobial agents.
  • a template (6 cm x 2 cm) was used in order to be able to apply all films in the same size.
  • the films were applied to the forearm and washes were performed. Washing procedure: films were rubbed with soap under warm water (36°C) for 5 minutes per wash to simulate handwashing.
  • Table 1 shows, by way of example, three preparations from the prior art with different concentrations of ethyl cellulose and different concentrations of glycerol and castor oil.
  • the wt% data relate to the weight of the amounts of the ingredient used in relation to the total weight of the formulation. Table 1 to be applied.
  • a first and general subject matter of the invention is an adhesive for gluing the wound:
  • Adhesion to the skin was determined as follows:
  • the films were applied to the forearm using a template (6 cm x 2 cm). How well a film adhered to the skin was determined by the time the film stayed on the skin before it came off on its own.
  • the water resistance was determined as follows:
  • the water resistance of the films was determined using washing processes.
  • the film was subjected to laundering operations until it broke and/or separated from the skin.
  • Table 3 shows the excellent effectiveness of a preparation according to the invention as an aerosol with the active ingredient octenidine against various pathogens.
  • the tests are carried out according to ISO 22196:2011 with the following microorganisms:
  • DSM 939 Pseudomonas aeruginosa

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Birds (AREA)
  • Emergency Medicine (AREA)
  • Materials Engineering (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne une préparation de fermeture de plaie constituée de matières premières à base naturelle, en particulier une préparation de fermeture de plaie à base biologique pulvérisable.
PCT/EP2022/050552 2021-02-03 2022-01-12 Préparation de fermeture de plaie à base biologique Ceased WO2022167183A1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP22701328.1A EP4288121A1 (fr) 2021-02-03 2022-01-12 Préparation de fermeture de plaie à base biologique
AU2022216364A AU2022216364A1 (en) 2021-02-03 2022-01-12 Bio-based wound closure preparation
MX2023009152A MX2023009152A (es) 2021-02-03 2022-01-12 Preparacion para el cierre de heridas de base biologica.
CA3208632A CA3208632A1 (fr) 2021-02-03 2022-01-12 Preparation de fermeture de plaie a base biologique

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102021200975.1A DE102021200975B4 (de) 2021-02-03 2021-02-03 Biologisch-basierte Wundverschlusszubereitung
DE102021200975.1 2021-02-03

Publications (1)

Publication Number Publication Date
WO2022167183A1 true WO2022167183A1 (fr) 2022-08-11

Family

ID=80122212

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2022/050552 Ceased WO2022167183A1 (fr) 2021-02-03 2022-01-12 Préparation de fermeture de plaie à base biologique

Country Status (6)

Country Link
EP (1) EP4288121A1 (fr)
AU (1) AU2022216364A1 (fr)
CA (1) CA3208632A1 (fr)
DE (1) DE102021200975B4 (fr)
MX (1) MX2023009152A (fr)
WO (1) WO2022167183A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024022671A1 (fr) * 2022-07-26 2024-02-01 Beiersdorf Ag Procédé de protection de la peau lors du retrait de revêtements de peau collés
WO2024027978A1 (fr) * 2022-08-02 2024-02-08 Beiersdorf Ag Revêtement de surface hydrophobe durable
WO2024027979A1 (fr) * 2022-08-02 2024-02-08 Beiersdorf Ag Revêtement hydrophobe durable pour produits médicaux

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102023211311A1 (de) 2023-11-14 2025-05-15 Beiersdorf Aktiengesellschaft Wundverschlusszubereitung auf Basis natürlicher Rohstoffe

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2343923A1 (de) 1973-08-31 1975-03-27 Beiersdorf Ag Filmbildende, verspruehbare polymerisatloesung zur herstellung eines wundverbandes (wundverband-spray)
DE2924042B1 (de) 1979-06-15 1980-02-14 Beiersdorf Ag Filmibildende,verspruehbare Polymerisatloesung zur Herstellung eines Wundverbandes
DE19841794A1 (de) * 1998-09-12 2000-03-16 Beiersdorf Ag Kombinationen von Antiadhäsiva (Ceramide und Sphingosine und Derivate) und Mikrobiziden
WO2008133918A1 (fr) * 2007-04-24 2008-11-06 Rutgers, The State University Of New Jersey Compositions de pansement et procédés
FR2972928A1 (fr) * 2011-03-25 2012-09-28 Urgo Lab Composition contenant une cellulose, une huile vegetale et un solvant volatil, ses utilisations comme pansement
WO2013159865A1 (fr) * 2012-04-25 2013-10-31 Merck Patent Gmbh Utilisation de dérivés de dicyclohexyl-méthanol présentant des propriétés antimicrobiennes
US9085608B2 (en) 2008-10-02 2015-07-21 Lytix Biopharma As Treatment of biofilms
US9556223B2 (en) 2008-10-02 2017-01-31 Lytix Biopharma As Antimicrobial compounds
FR3064488A1 (fr) 2017-03-31 2018-10-05 Urgo Recherche Innovation Et Developpement Composition contenant un derive de cellulose, un plastifiant, un solvant volatil et un actif, ses utilisations comme pansement
SE1751277A1 (en) 2017-10-13 2019-04-14 Amferia Ab Amphiphilic antimicrobial hydrogel
EP2196225B1 (fr) 2008-12-09 2019-10-16 Beiersdorf AG Matières actives hydrosolubles dans des préparations à base d'acrylate

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2343923A1 (de) 1973-08-31 1975-03-27 Beiersdorf Ag Filmbildende, verspruehbare polymerisatloesung zur herstellung eines wundverbandes (wundverband-spray)
DE2924042B1 (de) 1979-06-15 1980-02-14 Beiersdorf Ag Filmibildende,verspruehbare Polymerisatloesung zur Herstellung eines Wundverbandes
DE19841794A1 (de) * 1998-09-12 2000-03-16 Beiersdorf Ag Kombinationen von Antiadhäsiva (Ceramide und Sphingosine und Derivate) und Mikrobiziden
WO2008133918A1 (fr) * 2007-04-24 2008-11-06 Rutgers, The State University Of New Jersey Compositions de pansement et procédés
US9085608B2 (en) 2008-10-02 2015-07-21 Lytix Biopharma As Treatment of biofilms
US9556223B2 (en) 2008-10-02 2017-01-31 Lytix Biopharma As Antimicrobial compounds
EP2196225B1 (fr) 2008-12-09 2019-10-16 Beiersdorf AG Matières actives hydrosolubles dans des préparations à base d'acrylate
FR2972928A1 (fr) * 2011-03-25 2012-09-28 Urgo Lab Composition contenant une cellulose, une huile vegetale et un solvant volatil, ses utilisations comme pansement
WO2013159865A1 (fr) * 2012-04-25 2013-10-31 Merck Patent Gmbh Utilisation de dérivés de dicyclohexyl-méthanol présentant des propriétés antimicrobiennes
FR3064488A1 (fr) 2017-03-31 2018-10-05 Urgo Recherche Innovation Et Developpement Composition contenant un derive de cellulose, un plastifiant, un solvant volatil et un actif, ses utilisations comme pansement
SE1751277A1 (en) 2017-10-13 2019-04-14 Amferia Ab Amphiphilic antimicrobial hydrogel
SE541313C2 (en) 2017-10-13 2019-06-25 Amferia Ab Amphiphilic antimicrobial hydrogel

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024022671A1 (fr) * 2022-07-26 2024-02-01 Beiersdorf Ag Procédé de protection de la peau lors du retrait de revêtements de peau collés
WO2024027978A1 (fr) * 2022-08-02 2024-02-08 Beiersdorf Ag Revêtement de surface hydrophobe durable
WO2024027979A1 (fr) * 2022-08-02 2024-02-08 Beiersdorf Ag Revêtement hydrophobe durable pour produits médicaux

Also Published As

Publication number Publication date
EP4288121A1 (fr) 2023-12-13
CA3208632A1 (fr) 2022-08-11
MX2023009152A (es) 2023-08-17
DE102021200975B4 (de) 2022-11-24
DE102021200975A1 (de) 2022-08-04
AU2022216364A1 (en) 2023-07-20

Similar Documents

Publication Publication Date Title
DE102021200975B4 (de) Biologisch-basierte Wundverschlusszubereitung
EP0060553B1 (fr) Médicament pour le traitement des blessures de la surface dermique et procédé de préparation dudit médicament
EP2196225B1 (fr) Matières actives hydrosolubles dans des préparations à base d'acrylate
EP0280915A2 (fr) Préparations à usage topique d'inhibiteurs de gyrase en combinaison avec des corticostéroides
EP0308436B1 (fr) Onguent medicinal, son procede de production, formes d'application utilisant cet onguent et sa production
DE1467921A1 (de) Verfahren zur Herstellung von therapeutischen oder kosmetischen Mitteln fuer die topische Anwendung
WO2007115635A1 (fr) Liposomes contenant du biguanide
JPS5944313A (ja) 抗菌性組成物
DE60018409T2 (de) Verwendung von antiseptika zur herstelllung von arzneimitteln zur prophylaxe und behandlung von infektionen und/ oder funktionellen gewebeumformungen im körperinneren
DE3632222A1 (de) Topisch anwendbare zubereitungen von gyrase-inhibitoren
CN107205375A (zh) 杀微生物用水包油型分散液
DE69328228T2 (de) Wundheilmittel
DE102007030103A1 (de) Verwendung einer synergistischen Zusammensetzung als therapeutisches oder kosmetisches Mittel
WO2022053220A1 (fr) Préparation de fermeture de plaie contenant une substance active
DE102020204730A1 (de) Hautdesinfektionsmittel
WO2022053222A1 (fr) Préparation de fermeture de plaie contenant une substance active
DE102020204728A1 (de) Hautdesinfektionsmittel
WO2024027979A1 (fr) Revêtement hydrophobe durable pour produits médicaux
DE2415750A1 (de) Mittel zur bekaempfung von mikroorganismen
DE69419023T2 (de) Aerosol-zusammensetzung geeignet zur bildung einer vorzugsweise hydrierten membran, derart erhaltene vorzugsweise hydrierte membran und ihre anwendungen, insbesondere als verbandmaterial
WO2025103709A1 (fr) Préparation pour fermeture de plaie à base de matières premières naturelles
RU2691113C2 (ru) Средство для лечения кожных ран у животных и способ его применения
DE1492014C (de) Mittel zur Entfernung von Ohren schmalz
WO2025224246A1 (fr) Couche de contact avec une plaie dotée de propriétés d'inhibition d'infection
WO2024022671A1 (fr) Procédé de protection de la peau lors du retrait de revêtements de peau collés

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22701328

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3208632

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2022216364

Country of ref document: AU

Date of ref document: 20220112

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: MX/A/2023/009152

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2022701328

Country of ref document: EP

Effective date: 20230904